<DOC>
	<DOCNO>NCT00003713</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness intoplicine treat patient advanced metastatic solid tumor .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine intolerable dose level intoplicine patient locally advanced metastatic cancer . II . Determine recommend phase II dose intoplicine patient . III . Determine principal dose limit toxicity intoplicine patient , determine duration reversibility toxicity . IV . Determine magnitude plasma concentration achieve maintained regimen relate parameter toxicity outcome antitumor activity . V. Determine preliminary evidence antitumor activity intoplicine patient . OUTLINE : This dose escalation study . The first 3 patient receive intoplicine IV continuous infusion 5 day . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Subsequent cohort 3-6 patient receive escalate dos intoplicine , first increase number day drug infuse 10 , 15 , 21 , increase dosage keep infusion time constant 21 day . The intolerable dose level define low dose least 2 3 6 patient experience dose limit toxicity course 1 2 . PROJECTED ACCRUAL : A total 20-35 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven solid tumor refractory conventional cytotoxic anticancer therapy curative therapy exist Measurable evaluable disease No active , progressive brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 mg/dL SGOT/SGPT great 3 time upper limit normal No nonmalignant hepatic disease Renal : Creatinine great 2.0 mg/dL Potassium magnesium least low limit normal ( LLN ) Calcium least LLN Cardiovascular : QTc interval echocardiogram le 450 milliseconds No myocardial infarction within past 6 month No uncontrolled congestive heart failure No unstable angina No active cardiomyopathy No unstable ventricular arrhythmia No uncontrolled hypertension Other : Not pregnant nursing Fertile patient must use effective contraception Must functional central venous access device percutaneous intravenous catheter No known hypersensitivity intoplicine analogs No active alcoholism drug addiction No uncontrolled , unstable psychotic disorder No serious infection No underlie medical condition may aggravate treatment PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent antineoplastic therapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy ( except short course ( great 5 fraction ) nonmyelosuppressive , palliative radiotherapy ) recover No concurrent radiotherapy Surgery : Not specify Other : At least 3 week since prior investigational therapy No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>